Browsing by Author "Aksu, Kenan"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Publication Identification of susceptibility loci for takayasu arteritis through a large multi-ancestral genome-wide association study(Cell Press, 2021-01-07) Ortiz-Fernandez, Lourdes; Saruhan-Direskeneli, Guher; Alibaz-Oner, Fatma; Kaymaz-Tahra, Sema; Coit, Patrick; Kong, Xiufang; Kiprianos, Allan P.; Maughan, Robert T.; Aydin, Sibel Z.; Aksu, Kenan; Keser, Gokhan; Kamali, Sevil; Inanc, Murat; Springer, Jason; Akar, Servet; Onen, Fatos; Akkoc, Nurullah; Khalidi, Nader A.; Koening, Curry; Karadag, Omer; Kiraz, Sedat; Forbess, Lindsy; Langford, Carol A.; McAlear, Carol A.; Ozbalkan, Zeynep; Yavuz, Sule; Cetin, Gozde Yildirim; Alpay-Kanitez, Nilufer; Chung, Sharon; Ates, Askin; Karaaslan, Yasar; McKinnon-Maksimowicz, Kathleen; Monach, Paul A.; Ozer, Huseyin T. E.; Seyahi, Emire; Fresko, Izzet; Cefle, Ayse; Seo, Philip; Warrington, Kenneth J.; Ozturk, Mehmet A.; Ytterberg, Steven R.; Cobankara, Veli; Onat, Ahmet Mesut; Duzgun, Nursen; Bicakcigil, Muge; Yentur, Sibel P.; Lally, Lindsay; Manfredi, Angelo A.; Baldissera, Elena; Erken, Eren; Yazici, Ayten; Kisacik, Bunyamin; Kasifoglu, Timucin; Dalkilic, Ediz; Cuthbertson, David; Pagnoux, Christian; Sreih, Antoine; Reales, Guillermo; Wallace, Chris; Wren, Jonathan D.; Cunninghame-Graham, Deborah S.; Vyse, Timothy J.; Sun, Ying; Chen, Huiyong; Grayson, Peter C.; Tombetti, Enrico; Jiang, Lindi; Mason, Justin C.; Merkel, Peter A.; Direskeneli, Haner; Sawalha, Amr H.; 0000-0002-0247-4280; 0000-0003-0660-764X; 0000-0003-4153-903X; 0000-0001-7289-1816; 0000-0002-6376-5583; 0000-0002-3734-1242; 0000-0002-6341-2622; 0000-0002-3718-171X; 0000-0002-8270-2617; 0000-0003-1372-1555; 0000-0003-1185-5816; 0000-0003-4937-0515; 0000-0001-8764-4543; 0000-0003-4965-2918; 0000-0002-8914-9690; 0000-0001-7708-2487; 0000-0002-4530-7167; 0000-0002-7054-1203; 0000-0003-2167-4509; 0000-0002-3785-9834; 0000-0001-6287-9549; 0000-0002-7864-0185; 0000-0001-9993-3916; 0000-0001-9755-1703; 0000-0003-2776-3545; 0000-0003-1123-1464; 0000-0002-7122-9713; 0000-0001-7783-1660; 0000-0001-9284-7345; 0000-0003-2598-5806; GPP-1272-2022; CAG-1626-2022; ISU-1002-2023; D-2668-2012; AAA-6647-2020; AAT-3653-2020; HLH-8218-2023; AAT-3636-2020; KLZ-4006-2024; W-7332-2019; D-9870-2011; GOJ-7451-2022; C-4612-2015; KHW-8303-2024; AAD-5448-2019; AAA-8970-2021; P-4517-2015; L-1241-2015; HJI-6996-2023; JFJ-3399-2023; AAB-3576-2020; C-7018-2014; K-5378-2018Takayasu arteritis is a rare inflammatory disease of large arteries. We performed a genetic study in Takayasu arteritis comprising 6,670 individuals (1,226 affected individuals) from five different populations. We discovered HLA risk factors and four non-HLA susceptibility loci in VPS8, SVEP1, CFL2, and chr13q21 and reinforced IL12B, PTK2B, and chr21q22 as robust susceptibility loci shared across ancestries. Functional analysis proposed plausible underlying disease mechanisms and pinpointed ETS2 as a potential causal gene for chr21q22 association. We also identified >60 candidate loci with suggestive association (p < 5 x 10(-s)) and devised a genetic risk score for Takayasu arteritis. Takayasu arteritis was compared to hundreds of other traits, revealing the closest genetic relatedness to inflammatory bowel disease. Epigenetic patterns within risk loci suggest roles for monocytes and B cells in Takayasu arteritis. This work enhances understanding of the genetic basis and pathophysiology of Takayasu arteritis and provides clues for potential new therapeutic targets.Item Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases(J Rheumatol Publication, 2015-09) Yılmaz, Neslihan; Emmungil, Hakan; Gücenmez, Sercan; Özen, Gülşen; Yıldız, Fatih; Balkarlı, Ayşe; Kimyon, Gezmiş; Doğan, İsmail; Pamuk, Ömer Nuri; Yaşar, Şule; Çetin, Gözde Yıldırım; Yazıcı, Ayten; Eşmen, Serpil Ergülü; Cağatay, Yonca; Yılmaz, Sema; Cefle, Ayşe; Sayarlıoğlu, Mehmet; Kaşifoğlu, Timuçin; Karadağ, Ömer; KIsacık, Bünyamin; Çobankara, Veli; Erken, Eren; Direskeneli, Haner; Aksu, Kenan; Yavuz, Şule; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0003-0298-4157; AAG-8227-2021; AAG-7155-2021; 55646165400; 57220381538; 6506739457Objective. To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases. Methods. Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics. Results. We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4-48) and bladder cancer was 8 years (6-10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis. Conclusion. Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort.